Jiangsu Hengrui Pharma 
Welcome,         Profile    Billing    Logout  
 196 Products   52 Diseases   196 Products   3529 Trials   15381 News 


«12...182183184185186187188189190191192...208209»
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    New P2 trial, Real-world evidence:  RFA Plus Carrizumab vs Carrizumab Alone for HCC (clinicaltrials.gov) -  Nov 8, 2019   
    P2,  N=120, Recruiting, 
  • ||||||||||  vinorelbine tartrate / Generic mfg., Rituxan (rituximab) / Roche, Biogen
    Efficacy and Safety of PD-1 Inhibitor Plus GVD Chemotherapy in Patients with Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (rrPMLBCL) (Hall B, Level 2 (Orange County Convention Center)) -  Nov 7, 2019 - Abstract #ASH2019ASH_5808;    
    All enrolled patients received combining PD-1 blockade using Camrelizumab with GVD chemotherapy (gemcitabine, vinorelbine and pegylated liposomal doxorubicin)every 3 weeks until the patients achieved second assessable complete response or up to 12 cycles, followed by maintenance camrelizumab monotherapy up to 1 year...Results At the analysis cutoff date (March 31, 2019), 27 rrPMLBCL patients were enrolled: median age 30 years (range: 18-45), 52% female (14/27), median 3 lines of prior therapy (range: 2-6), median 6 cycles of rituximab-containing regimens (range: 2-10)...Aside from palliation, new salvage therapeutic strategies are urgently needed. Camrelizumab plus GVD chemotherapy should be considered as a compelling new standard of salvage therapy with promising efficacy and manageable safety profile for patients with rrPMBCL.
  • ||||||||||  TG-1701 / TG Therapeutics
    Phase 1 Study of TG-1701, a Selective Irreversible Inhibitor of Bruton's Tyrosine Kinase (BTK), in Patients with Relapsed/Refractory B-Cell Malignancies (Hall B, Level 2 (Orange County Convention Center)) -  Nov 7, 2019 - Abstract #ASH2019ASH_5734;    
    P1
    TG-1701 is a novel, orally available and covalently-bound BTK inhibitor that exhibits superior selectivity for BTK compared with ibrutinib in in vitro whole kinome screening (Abstr 3973, EHA 2018)...Patients in the 1701 + U2 combination arm receive escalating TG-1701 oral QD + umbralisib 800 mg oral QD + ublituximab 900 mg IV on D1, 8, 15 of C1, and D1 of C2-6...Conclusions TG-1701, a once daily BTK inhibitor has an encouraging preliminary safety profile, with clinical and pharmacodynamic activity at all dose levels evaluated . This study (NCT03671590) continues enrollment in TG-1701 single-agent and 1701 + U2 combination arms.
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Trial completion date, Trial primary completion date, Metastases:  Poetry-1: Apatinib for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment (clinicaltrials.gov) -  Nov 6, 2019   
    P2,  N=43, Recruiting, 
    Further investigations into this topic will be of profound significance. Trial completion date: Feb 2019 --> Dec 2022 | Trial primary completion date: Dec 2018 --> Dec 2019
  • ||||||||||  famitinib (SHR 1020) / Jiangsu Hengrui Pharma
    Trial completion date, Trial suspension, Trial primary completion date:  A Study of Famitinib in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) -  Nov 4, 2019   
    P2,  N=137, Suspended, 
    Trial completion date: Feb 2019 --> Dec 2022 | Trial primary completion date: Dec 2018 --> Dec 2019 Trial completion date: Jun 2019 --> Jun 2020 | Active, not recruiting --> Suspended | Trial primary completion date: Jun 2019 --> Jun 2020
  • ||||||||||  AiRuiEn (rezvilutamide) / Jiangsu Hengrui Pharma
    Enrollment change, Trial primary completion date:  A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients (clinicaltrials.gov) -  Nov 3, 2019   
    P1/2,  N=200, Recruiting, 
    Moreover, Apatinib synergized with Paclitaxel to achieve more significant suppression on tumor growth, proposing that Apatinib might be a potent drug for cervical cancer. N=140 --> 200 | Trial primary completion date: Jul 2018 --> Dec 2019
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, Keytruda (pembrolizumab) / Merck (MSD)
    Enrollment closed, Metastases:  APPEASE: Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies (clinicaltrials.gov) -  Nov 2, 2019   
    P1/2,  N=119, Active, not recruiting, 
    N=140 --> 200 | Trial primary completion date: Jul 2018 --> Dec 2019 Recruiting --> Active, not recruiting
  • ||||||||||  Clinical, Review, Journal:  Marine-Derived Anticancer Agents: Clinical Benefits, Innovative Mechanisms, and New Targets. (Pubmed Central) -  Nov 2, 2019   
    Approximately 50 years since the approval of cytarabine, the marine-derived anticancer pharmaceutical pipeline includes four approved drugs and eighteen agents in clinical trials, six of which are in late development. Thus, the dynamic pharmaceutical pipeline consisting of approved and developmental marine-derived anticancer agents offers new hopes and new tools in the treatment of patients afflicted with previously intractable types of cancer.
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
    Trial primary completion date, PD(L)-1 Biomarker, IO biomarker:  A Trial of SHR-1210 (an Anti-PD-1 Antibody) in Combination With Apatinib in Patients With Advanced TNBC (clinicaltrials.gov) -  Oct 22, 2019   
    P2,  N=58, Active, not recruiting, 
    PDX models with defined molecular signature are useful for preclinical studies with targeted drugs, and the results should be validated in larger studies with PDX models or in clinical trials. Trial primary completion date: Sep 2019 --> Jun 2020
  • ||||||||||  Herceptin (trastuzumab) / Roche, paclitaxel / Generic Mfg., Opdivo (nivolumab) / Ono Pharma, BMS
    Review, Journal:  Targeted and novel therapy in advanced gastric cancer. (Pubmed Central) -  Oct 22, 2019   
    Pembrolizumab has demonstrated more than 50% response rate in microsatellite instability-high tumors, 15% response rate in tumors expressing programmed death ligand 1, and non-inferior outcome in first-line treatment compared to chemotherapy. This review summarizes the current state and progress of research on targeted therapy for advanced GC.
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical
    Clinical, Journal:  The efficacy and safety of anlotinib treatment for advanced lung cancer. (Pubmed Central) -  Oct 17, 2019   
    In the third-line or more-line treatment of advanced lung cancer, anlotinib appears to have some activity when utilized as a salvage treatment. Adverse reactions are controllable.
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Enrollment closed, Trial completion date, Trial primary completion date, Tumor mutational burden:  LSK-AM107: A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic Cancer (clinicaltrials.gov) -  Oct 11, 2019   
    P1,  N=30, Active, not recruiting, 
    This study provides a practical basis for the phenotypic-, biochemical- and structure-directed discovery of novel antifungals that target LDMs of fungal pathogens. Recruiting --> Active, not recruiting | Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Sep 2019 --> Jun 2020
  • ||||||||||  AiTan (rivoceranib) / LSK BioPartners
    Preclinical, Journal:  Antitumor Activity of Rivoceranib Against Canine Mammary Gland Tumor Cell Lines. (Pubmed Central) -  Oct 10, 2019   
    Recruiting --> Active, not recruiting | Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Sep 2019 --> Jun 2020 We confirm that rivoceranib exerts antitumor effects on CMGT cells by inhibiting biological functions.
  • ||||||||||  paclitaxel / Generic Mfg.
    Review, Journal:  Anti-angiogenic therapies for gastric cancer. (Pubmed Central) -  Oct 8, 2019   
    Additionally, apatinib, a selective VEGFR-2 tyrosine kinase inhibitor, prolonged survival as a third-line or later treatment option in patients with advanced gastric cancer...A global phase III trial comparing regorafenib with placebo is currently ongoing. Further studies of anti-angiogenic therapy combined with not only chemotherapy but also immune checkpoint inhibitors are also being pursued, providing hope for improved survival in patients with gastric cancer.